Indication
Hypertension
The Hypertension pipeline: 68 tracked drugs, 7 approved for this indication.
7 approved / phase 425 Phase 31 Phase 2/314 Phase 22 Phase 1/29 Phase 110 preclinical / unstaged
Compare the share prices of listed companies in Hypertension →
Total attributable cost
$347.4B
$2,759/patient
Drug spend
$34.6B
$275/patient
10% of total cost is drugs
All severities (2017 ACC/AHA threshold) · US